Messing Vera - Academia.edu (original) (raw)

Papers by Messing Vera

published in Hungarian with the title 'Szélre tolva. Kutatási zárójelentés a roma közösségek több... more published in Hungarian with the title 'Szélre tolva. Kutatási zárójelentés a roma közösségek többségi médiaképéről, 2011'. This working paper discusses results of a content analysis of the coverage of Roma by the mainstream media in 2011. The analysis is a continuation of the authors two decades' long cooperation uncovering and analysing the ways in which mainstream media represents Hungary's Roma communities and contributes to the reproduction of public stereotypes about this ethnic group. The research based on which the report was drafted analysed a wide range of media including largest political dailies, weekly papers, tabloid dailies, internet news portals, and TV news programs. Special attention was paid to the thorough analysis of the visual images published in newspapers and TV news programs.

Ethnic and Racial Studies, 2016

Background This phase 3 trial is the first to evaluate the efficacy and safety of treatment with ... more Background This phase 3 trial is the first to evaluate the efficacy and safety of treatment with the systemic TNF-a inhibitor, adalimumab, for Chinese patients with moderate-to-severe plaque psoriasis. Methods In the 12-week, double-blind, placebo-controlled Period A, patients were randomized 4 : 1 to receive adalimumab 40 mg every-other-week (following a single 80 mg dose), or placebo every-other-week. In the subsequent 12week, open-label, Period B, all patients received adalimumab 40 mg every-other-week starting at week 13, following a single, blinded dose at week 12 of adalimumab 80 mg or matching placebo (for patients receiving placebo or adalimumab in Period A respectively). In Period A, efficacy was analysed for all randomized patients and safety for all patients receiving ≥1 dose of the study drug. Results For the 425 patients in this study (87 placebo; 338 adalimumab), a higher percentage randomized to adalimumab achieved the primary endpoint of ≥75% improvement from baseline in PASI score (PASI 75) at week 12: placebo 11.5% (10/87); adalimumab 77.8% (263/338; P < 0.001). Physician's Global Assessment of clear to minimal was achieved at week 12 by 14.9% placebo (13/87) and 80.5% adalimumab (272/338; P < 0.001). For patients who received adalimumab at any time during the study (All-adalimumab Population), treatment-emergent adverse events (AEs) were reported by 63.4%; the most common was upper respiratory infection (16.1%). Serious AEs were reported by 3.5% of the All-adalimumab Population, and serious infectious AEs by 1.2%, which include lung infection, pneumonia and tuberculosis [2 (0.5%) patients each]. There was one death (chronic heart failure). Conclusion In these Chinese patients with moderate-to-severe psoriasis, a significantly greater percentage treated with adalimumab compared with placebo achieved efficacy endpoints at week 12 and efficacy was sustained to week 24. Safety results were consistent with the known adalimumab safety profile; no new safety signals were identified in the 24 weeks of treatment.

Intersections, 2018

This article is dedicated to Julia Szalai who researches the underlying reasons, consequences and... more This article is dedicated to Julia Szalai who researches the underlying reasons, consequences and mechanisms of the social exclusion of the Roma in Central and East European societies. Her work and her writings serve as a compass for those who examine problems of social exclusion, including the authors of this article. The present paper discusses position of the Roma on the Hungarian job-market, focusing on highly-qualified young Roma within the context of the business sphere. Our knowledge is informed by the first results of an initiative which creates bridges between disadvantaged social groups and the business sector through pro-active measures. The initiative mobilizes multinational companies, business trainers, NGOs promoting social inclusion, and academics. Both the initiative and our study intend to pursue a subtle understanding of the tangible and hidden obstacles that highly educated young Roma encounter when seeking employment, and of the dilemmas that multinational compan...

This paper aims to inquire into the potential of active labour market policies (LMP) to reach out... more This paper aims to inquire into the potential of active labour market policies (LMP) to reach out to unemployed Roma population in Hungary and in Spain.
While in Hungary unemployed Roma people are mainly thought to be
reached through mainstream measures, Spain represents a more complex regime with an emphasis on ethnically targeted programmes. Our analysis draws on a wider comparative research project (NEUJOBS) conducted in 2012/2013 and provides an insight into how LMP function locally for unemployed Roma. We conclude that there are two intersecting challenges regarding the success of LMP that aim to influence the employment situation of the Roma: the targeting strategies and the quality and complexity of the programmes’
design. Our empirical data suggest that both aspects need to be given equal attention in order to promote the inclusion of the Roma into the labour market.

published in Hungarian with the title 'Szélre tolva. Kutatási zárójelentés a roma közösségek több... more published in Hungarian with the title 'Szélre tolva. Kutatási zárójelentés a roma közösségek többségi médiaképéről, 2011'. This working paper discusses results of a content analysis of the coverage of Roma by the mainstream media in 2011. The analysis is a continuation of the authors two decades' long cooperation uncovering and analysing the ways in which mainstream media represents Hungary's Roma communities and contributes to the reproduction of public stereotypes about this ethnic group. The research based on which the report was drafted analysed a wide range of media including largest political dailies, weekly papers, tabloid dailies, internet news portals, and TV news programs. Special attention was paid to the thorough analysis of the visual images published in newspapers and TV news programs.

Ethnic and Racial Studies, 2016

Background This phase 3 trial is the first to evaluate the efficacy and safety of treatment with ... more Background This phase 3 trial is the first to evaluate the efficacy and safety of treatment with the systemic TNF-a inhibitor, adalimumab, for Chinese patients with moderate-to-severe plaque psoriasis. Methods In the 12-week, double-blind, placebo-controlled Period A, patients were randomized 4 : 1 to receive adalimumab 40 mg every-other-week (following a single 80 mg dose), or placebo every-other-week. In the subsequent 12week, open-label, Period B, all patients received adalimumab 40 mg every-other-week starting at week 13, following a single, blinded dose at week 12 of adalimumab 80 mg or matching placebo (for patients receiving placebo or adalimumab in Period A respectively). In Period A, efficacy was analysed for all randomized patients and safety for all patients receiving ≥1 dose of the study drug. Results For the 425 patients in this study (87 placebo; 338 adalimumab), a higher percentage randomized to adalimumab achieved the primary endpoint of ≥75% improvement from baseline in PASI score (PASI 75) at week 12: placebo 11.5% (10/87); adalimumab 77.8% (263/338; P < 0.001). Physician's Global Assessment of clear to minimal was achieved at week 12 by 14.9% placebo (13/87) and 80.5% adalimumab (272/338; P < 0.001). For patients who received adalimumab at any time during the study (All-adalimumab Population), treatment-emergent adverse events (AEs) were reported by 63.4%; the most common was upper respiratory infection (16.1%). Serious AEs were reported by 3.5% of the All-adalimumab Population, and serious infectious AEs by 1.2%, which include lung infection, pneumonia and tuberculosis [2 (0.5%) patients each]. There was one death (chronic heart failure). Conclusion In these Chinese patients with moderate-to-severe psoriasis, a significantly greater percentage treated with adalimumab compared with placebo achieved efficacy endpoints at week 12 and efficacy was sustained to week 24. Safety results were consistent with the known adalimumab safety profile; no new safety signals were identified in the 24 weeks of treatment.

Intersections, 2018

This article is dedicated to Julia Szalai who researches the underlying reasons, consequences and... more This article is dedicated to Julia Szalai who researches the underlying reasons, consequences and mechanisms of the social exclusion of the Roma in Central and East European societies. Her work and her writings serve as a compass for those who examine problems of social exclusion, including the authors of this article. The present paper discusses position of the Roma on the Hungarian job-market, focusing on highly-qualified young Roma within the context of the business sphere. Our knowledge is informed by the first results of an initiative which creates bridges between disadvantaged social groups and the business sector through pro-active measures. The initiative mobilizes multinational companies, business trainers, NGOs promoting social inclusion, and academics. Both the initiative and our study intend to pursue a subtle understanding of the tangible and hidden obstacles that highly educated young Roma encounter when seeking employment, and of the dilemmas that multinational compan...

This paper aims to inquire into the potential of active labour market policies (LMP) to reach out... more This paper aims to inquire into the potential of active labour market policies (LMP) to reach out to unemployed Roma population in Hungary and in Spain.
While in Hungary unemployed Roma people are mainly thought to be
reached through mainstream measures, Spain represents a more complex regime with an emphasis on ethnically targeted programmes. Our analysis draws on a wider comparative research project (NEUJOBS) conducted in 2012/2013 and provides an insight into how LMP function locally for unemployed Roma. We conclude that there are two intersecting challenges regarding the success of LMP that aim to influence the employment situation of the Roma: the targeting strategies and the quality and complexity of the programmes’
design. Our empirical data suggest that both aspects need to be given equal attention in order to promote the inclusion of the Roma into the labour market.